WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101 - Seite 2

Prof. David Walker comments, “I have been involved in initiating the children’s brain tumour drug delivery consortium (www.cbtddc.org) as a research initiative to raise awareness of the opportunities for optimising drug delivery for the treatment of children’s brain tumours. This initiative has attracted significant clinical, academic and commercial interest as a strategy for children’s brain tumours with overlapping technical opportunities in adult neuro oncology practice.  Low-grade glioma are a developmental abnormality in children’s brains accounting for 40% of all brain tumours in this age group. The molecular changes are increasingly being clarified and tested as drug targets. High grade glioma in children have significant overlap with the same tumours in adulthood but also significant differences,  anatomically and biologically. Current treatments are relatively ineffective and have high risk of brain damage linked to the use of radiation. Investigating novel drug delivery methods offers an opportunity to enhance the efficacy and reduce brain damaging toxicity. WPD Pharmaceuticals has appreciated the opportunities for optimising drug delivery as a strategy in this group of brain diseases across all ages.”

WPD also announces that it has engaged Arrowhead Business and Investment Decisions, LLC., (“Arrowhead”) to provide investor relations support and brand awareness within the investment community. The Company has agreed to pay Arrowhead US$20,000 for a three month term, with the option to extend for another three month term at the same fixed cost. Arrowhead will not receive any securities of the Company as compensation for their services.

About WPD Pharmaceuticals

WPD is a biotechnology research and development company with a focus on oncology and virology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has licensed in certain countries 10 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at medical institutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things. The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes for most compounds 30 countries in Europe and Asia, including Russia.